Clinical Trials Logo

Filter by:
NCT ID: NCT04794595 Recruiting - Sepsis Clinical Trials

Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children

Start date: December 1, 2020
Phase:
Study type: Observational

The effect of continuous blood purification (CBP) in children is unclear. Also, the timing of early application is still being explored. In this study, we need to explore the efficacy and the timing of application of CBP in children with sepsis or septic shock.

NCT ID: NCT04794140 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

The Aim of this study is to investigate the amount of tissue required for the successful culture of primary cells from human-derived pancreatic ductal adenocarcinoma which obtained by endoscopic ultrasound-guided fine-needle biopsy wet suction technique

NCT ID: NCT04793672 Recruiting - Malignant Tumor Clinical Trials

Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis

Start date: April 6, 2021
Phase:
Study type: Observational [Patient Registry]

The tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database. Deep learning will be carried out by computer and artificial intelligence to construct the early screening, diagnosis, prognosis and prognosis model of various malignant tumors based on tongue image for the diagnosis and treatment of malignant tumors.

NCT ID: NCT04792593 Recruiting - B-ALL Clinical Trials

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: December 3, 2020
Phase: N/A
Study type: Interventional

This study is an open, dose-escalating clinical study, taking patients with relapsed or refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T treatment failure or relapse, or for any reason cannot bridge the transplant r/r B-ALL.

NCT ID: NCT04792515 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer

CCWSA/OAFLAG
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the efficacy and safety of camrelizumab in combination with SOX and/or apatinib in the treatment of locally advanced gastric cancer or gastroesophageal junction adenocarcinoma.The primary endpoint was pathologic complete response (PCR).In addition, secondary efficacy endpoints include R0 resection rate, objective response rate (ORR), and 1-year progression-free survival rate (PFSR) . They were set to demonstrate the therapeutic benefit of camrelizumab combined with SOX in patients 。

NCT ID: NCT04792437 Recruiting - Glioma Clinical Trials

Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data

Start date: March 10, 2021
Phase:
Study type: Observational

This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular biology technologies to jointly define the following research objectives :

NCT ID: NCT04790942 Recruiting - Hypertension Clinical Trials

Effect of Berberine Hydrochloride on Blood Pressure and Vascular Endothelial Function in Patients With Hypertension

Start date: October 22, 2020
Phase: Phase 4
Study type: Interventional

Hypertension is a progressive cardiovascular syndrome caused by multiple causes, which can lead to changes in the function and structure of the heart and blood vessels. It is the leading risk factor of cardiovascular disease. Berberine (BBR) hydrochloride is an isoquinoline alkaloid (chemical formula: C20H18NO4) extracted from traditional Chinese herb Coptis chinensis. It has been widely used to treat diarrhea and enteritis for hundreds of years in China. BBR has extremely high clinical application value. It is an over-the-counter drug with low price, good safety and few adverse reactions in China. We found that Berberine (BBR) hydrochloride tablets have a hypotensive effect in clinical practice. However, there are few clinical studies on the treatment of hypertensive patients with BBR tablets. In addition, the clinical dosage of BBR tablets is not uniform, and its molecular mechanism is still unclear. In order to further evaluate the clinical efficacy of BBR in reducing blood pressure and improving vascular endothelial injury, we carried out this clinical trial of drug intervention for hypertensive population. After signed the informed consent, the subjects are assigned to the lifestyle intervention group (CON) and berberine hydrochloride group (BBR). The berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months) . We will follow up blood pressure and vascular endothelial function in 1 month and 3 months after taking the medicine.

NCT ID: NCT04790747 Recruiting - Clinical trials for Hematological Malignancies

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Start date: March 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions

NCT ID: NCT04790305 Recruiting - Clinical trials for Triple-negative Breast Cancer

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Start date: June 18, 2021
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.

NCT ID: NCT04790084 Recruiting - Choroid Clinical Trials

Three-dimensional Choroidal Vascularity Index in Common Fundus Diseases

Start date: March 4, 2021
Phase:
Study type: Observational

Explore the changes of choroidal blood perfusion in common fundus diseases by three-dimensional choroidal vascularity index, an optical coherence tomography (OCT) parameter.